 Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- NIDDM
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
- Diabetes Mellitus, Noninsulin Dependent
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 2 | 2 | | 1986 | 1 | 0 | 1 | | 1988 | 6 | 0 | 6 | | 1989 | 4 | 0 | 4 | | 1990 | 4 | 1 | 5 | | 1991 | 3 | 0 | 3 | | 1992 | 11 | 1 | 12 | | 1993 | 6 | 1 | 7 | | 1994 | 10 | 2 | 12 | | 1995 | 21 | 3 | 24 | | 1996 | 22 | 1 | 23 | | 1997 | 18 | 3 | 21 | | 1998 | 6 | 4 | 10 | | 1999 | 5 | 1 | 6 | | 2000 | 25 | 6 | 31 | | 2001 | 11 | 4 | 15 | | 2002 | 18 | 5 | 23 | | 2003 | 7 | 6 | 13 | | 2004 | 21 | 5 | 26 | | 2005 | 27 | 4 | 31 | | 2006 | 28 | 6 | 34 | | 2007 | 20 | 6 | 26 | | 2008 | 28 | 8 | 36 | | 2009 | 19 | 9 | 28 | | 2010 | 25 | 6 | 31 | | 2011 | 31 | 9 | 40 | | 2012 | 26 | 6 | 32 | | 2013 | 34 | 5 | 39 | | 2014 | 42 | 6 | 48 | | 2015 | 29 | 5 | 34 | | 2016 | 40 | 4 | 44 | | 2017 | 26 | 6 | 32 | | 2018 | 36 | 7 | 43 | | 2019 | 9 | 1 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Laiteerapong N, Ham SA, Nathan AG, Sargis RM, Quinn MT, Huang ES. National physician survey on glycemic goals and medical decision making for patients with type 2 diabetes. Medicine (Baltimore). 2019 Dec; 98(51):e18491.
-
Lipska KJ, Laiteerapong N. Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial. N Engl J Med. 2019 06 06; 380(23):2266-2267.
-
Flannick J, Mercader JM, Fuchsberger C, Udler MS, Mahajan A, Wessel J, Teslovich TM, Caulkins L, Koesterer R, Barajas-Olmos F, Blackwell TW, Boerwinkle E, Brody JA, Centeno-Cruz F, Chen L, Chen S, Contreras-Cubas C, Córdova E, Correa A, Cortes M, DeFronzo RA, Dolan L, Drews KL, Elliott A, Floyd JS, Gabriel S, Garay-Sevilla ME, García-Ortiz H, Gross M, Han S, Heard-Costa NL, Jackson AU, Jørgensen ME, Kang HM, Kelsey M, Kim BJ, Koistinen HA, Kuusisto J, Leader JB, Linneberg A, Liu CT, Liu J, Lyssenko V, Manning AK, Marcketta A, Malacara-Hernandez JM, Martínez-Hernández A, Matsuo K, Mayer-Davis E, Mendoza-Caamal E, Mohlke KL, Morrison AC, Ndungu A, Ng MCY, O'Dushlaine C, Payne AJ, Pihoker C. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. Nature. 2019 06; 570(7759):71-76.
-
Sanyoura M, Letourneau L, Knight Johnson AE, Del Gaudio D, Greeley SAW, Philipson LH, Naylor RN. GCK-MODY in the US Monogenic Diabetes Registry: Description of 27 unpublished variants. Diabetes Res Clin Pract. 2019 May; 151:231-236.
-
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
-
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019 05 11; 393(10184):1937-1947.
-
Roberson KY, Van Gompel EW, Jarrett JB. Bariatric surgery + medical therapy: Effective Tx for T2DM? J Fam Pract. 2019 03; 68(2):102-104.
-
Laiteerapong N, Ham SA, Huang ES, Karter AJ. Response to Comment on Laiteerapong et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care 2019;42:416-426. Diabetes Care. 2019 03; 42(3):e46-e47.
-
Basu A, Sohn MW, Bartle B, Chan KCG, Cooper JM, Huang E. Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. Med Decis Making. 2019 02; 39(2):137-151.
-
Nagpal SJS, Chari ST. Immunoglobulin G4 Levels. JAMA. 2019 Jan 15; 321(2):202-203.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|